Q2-rapport
14 dagar sedan‧27min
Orderdjup
Antal
Köp
125
Sälj
Antal
100
Senaste avslut
| Tid | Pris | Antal | Köpare | Säljare |
|---|---|---|---|---|
| - | - | - | - |
Högst
-VWAP
Lägst
-Omsättning ()
VWAP
Högst
-Lägst
-Omsättning ()
Mäklarstatistik
Ingen data hittades
Företagshändelser
| Nästa händelse | |
|---|---|
Kalender är inte tillgänglig | |
| Tidigare händelser | ||
|---|---|---|
| 2025 Q2-rapport | 7 aug. | |
| 2025 Årsstämma | 12 juni | |
| 2025 Q1-rapport | 8 maj | |
| 2024 Q4-rapport | 27 feb. | |
| 2024 Årsrapport | 27 feb. |
Data hämtas från Morningstar, Quartr
Kunder har även besökt
Shareville
Delta i diskussionerna på SharevilleFå inspiration från tusentals portföljer och diskutera med andra duktiga investerare.
Logga in
för 2 dagar sedanför 2 dagar sedanI januari 2025 meddelade AbCellera att de expanderar sitt samarbete med AbbVie för att utveckla nya T-cell-engagerande antikroppar (TCE) inom onkologi. Samarbetet innebär: • AbCellera leder forsknings- och upptäcktsarbetet med sin avancerade TCE-plattform. • AbbVie har rätt att vidareutveckla och kommersialisera de terapeutiska antikropparna som tas fram. • AbCellera får upfront-betalningar, forskningsersättningar, milstolpsbetalningar och royalties baserat på försäljning . I slutet av juli tecknade AbbVie ett exklusivt licensavtal med IGI Therapeutics värt 700 miljoner USD för läkemedelskandidaten ISB 2001, riktad mot cancer och autoimmuna sjukdomar. Avtalet ger AbbVie rättigheter att utveckla och kommersialisera ISB 2001 i Nordamerika, Europa, Japan och Kina. Det inkluderar även potentiella milstolpsbetalningar upp till 1,225 miljarder USD samt tvåsiffriga royalties. Detta kommer skapa stora nya intäkter för Abcellera🚀
8 aug.8 aug.Fin rapport! 🚀 Spännande framtid 🤩 ABCL635 och ABCL575 avancerar mot fas 1 kliniska prövningar i Q2 2026, med fokus på vasomotoriska symtom (menopaus) och atopisk dermatit. Stark likviditet med $810M tillgängligt, inklusive $633M i kontanter och $178M i icke-utspädande statlig finansiering. Framsteg med fyra molekyler för onkologi och autoimmuna sjukdomar, med lovande prekliniska data. 97 partnerinitierade programstart (upp 8% YoY) och 16 molekyler i klinik (upp 23% YoY).
8 aug.8 aug.Clinical Program Updates AbCellera received Health Canada authorization to begin Phase I clinical trials for two internal antibody programs, ABCL635 (for vasomotor symptoms, VMS) and ABCL575 (for atopic dermatitis). Dosing has started for ABCL635, marking the company’s transition to a clinical-stage biotech. ABCL575’s trial was opened post-quarter, with dosing expected soon. A third program, ABCL688, targeting an undisclosed autoimmune indication, advanced into IND-enabling studies with an IND submission planned for mid-2026. ABCL635 Program for Vasomotor Symptoms ABCL635 is a potential first-in-class, nonhormonal NK3R antagonist designed to improve safety and dosing convenience. The Phase I trial is a randomized, placebo-controlled study assessing safety, pharmacokinetics, pharmacodynamics, and VMS frequency/severity with subcutaneous dosing. Primary endpoint is safety; key secondary endpoint is pharmacokinetics. Target engagement remains the main scientific risk, to be addressed via biomarkers and proof-of-concept studies. Initial safety and efficacy data are expected by mid-2026. Estimated enrollment around 56-60 participants across single and multiple ascending dose portions, with up to 80 postmenopausal women expected in proof-of-concept phases. There is a large market opportunity given many menopausal women are either contraindicated for or hesitant about hormone therapy, and NK3R antagonists are seen as complementary alternatives. Preclinical data supports a high concentration subcutaneous formulation aiming for once-monthly dosing. ABCL575 Program for Atopic Dermatitis ABCL575 targets the OX40 ligand, under development for moderate to severe atopic dermatitis and other immune/inflammatory conditions. The Phase I trial is double-blind, placebo-controlled, evaluating safety and tolerability in healthy participants. The antibody is engineered for half-life extension, with preclinical data indicating an approximate 67-day half-life to support twice-yearly subcutaneous dosing. Early focus is on bioavailability and pharmacokinetics; later stages likely to involve U.S. sites. Pipeline and Discovery Efforts The company continues internal discovery to build and expand the pipeline, adding new programs from discovery into IND-enabling studies in 2025. ABCL688 is the second program based on the GPCR and ion channel platform. Details are currently withheld for strategic reasons. Priorities for the year include advancing internal clinical programs, bringing clinical manufacturing capabilities online, and progressing discovery programs.8 aug.8 aug.Financial Performance and Position AbCellera ended Q2 2025 with approximately $580 million in cash and marketable securities plus $170 million in available government funding, totaling about $750 million in available liquidity. Revenue for the quarter was about $17 million, largely from research fees and a lump-sum licensing payment related to the Trianni acquisition. Research and development expenses were $39 million, down slightly from the prior year, reflecting ongoing investments in internal programs. Net loss was $35 million for the quarter, a slight improvement compared to $37 million in Q2 2024. Cash used in operating activities was approximately $44 million in the first half of 2025, with investment largely directed toward clinical manufacturing facilities. The new manufacturing facility is expected to be operational by year-end 2025. The company believes it has sufficient capital to fund pipeline investments for over three years. Regulatory and Development Considerations The recent PDUFA delay for Bayer's elinzanetant does not directly impact ABCL635’s regulatory path; the delay relates to Bayer needing to provide additional information. Regulatory focus for ABCL635 will center on demonstrating efficacy and safety, especially regarding liver toxicity signals seen with other NK3R antagonists and somnolence linked to NK1R activity, which AbCellera’s antibody avoids. Biomarkers such as LH, FSH, testosterone, and estradiol will be assessed early in trials as surrogate efficacy indicators before clinical proof-of-concept data. Clinical Trial Design and Strategy Initial Phase I studies include single ascending dose (SAD) cohorts with healthy men and postmenopausal women and multiple ascending dose (MAD) cohorts with only postmenopausal women. The company plans to engage with FDA for Phase II studies, likely including U.S. sites in later clinical phases for ABCL575. The clinical focus is to test dosing schedules, safety, bioavailability, and early efficacy signals supporting further development. Market and Competitive Landscape For ABCL635, the company projects a substantial market opportunity focused on patients unable or unwilling to use hormone therapy. The NK3R antagonist class has an established regulatory precedent, and AbCellera seeks to differentiate based on safety and dosing advantages. ABCL575 targets a growing class with broad potential beyond atopic dermatitis in immunology and inflammation. Intellectual Property and Legal General and administrative expenses include ongoing IP defense costs, reflecting ongoing protection of company innovations. Summary: AbCellera is advancing clinical programs ABCL635 and ABCL575 through early-stage human trials with data readouts expected in 2026, maintaining strong liquidity and investing in internal discovery and manufacturing capacity. The company is focused on demonstrating differentiated clinical profiles and progressing pipeline candidates efficiently.
24 juli24 juliNoen som vet om det var noen nyheter som kom, eller annet spesifikt, som kan ha påvirket det store hoppet på mandag? Jeg er opp 46% her etter å ha vært inne bare en snau måned, og har en lang tidshorisont, men lurer på om jeg skal ta ut litt gevinst i forkant av kvartalstallene, mon tro...
25 juli25 juliSkulle säga att det är nu fram till helår 2026 som någonstans blir make or break året för Abcellera, så är det någonstans du ska ligga stilla, så är det här. Vi kan se en halvering av kursen, eller en dubblering inom bara månader. Och blir det en kraftig uppsving med så många miljoner aktier kortade så blir det gissningsvis en flerdubblering. Uppsida här är enorm men med rejäl risk. Som alltid.
för 2 dagar sedanför 2 dagar sedanNo risk no reward right now I’m amazed by the advice I just got to buy some stock here
Kommentarerna ovan kommer från användare på Nordnets sociala nätverk Shareville och har varken redigerats eller på förhand granskats av Nordnet. Det innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna eller eventuella felaktigheter i automatiska översättningar.
Nyheter & Analyser
Det finns för närvarande inga nyheter
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Q2-rapport
14 dagar sedan‧27min
Nyheter & Analyser
Det finns för närvarande inga nyheter
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Shareville
Delta i diskussionerna på SharevilleFå inspiration från tusentals portföljer och diskutera med andra duktiga investerare.
Logga in
- för 2 dagar sedanför 2 dagar sedanI januari 2025 meddelade AbCellera att de expanderar sitt samarbete med AbbVie för att utveckla nya T-cell-engagerande antikroppar (TCE) inom onkologi. Samarbetet innebär: • AbCellera leder forsknings- och upptäcktsarbetet med sin avancerade TCE-plattform. • AbbVie har rätt att vidareutveckla och kommersialisera de terapeutiska antikropparna som tas fram. • AbCellera får upfront-betalningar, forskningsersättningar, milstolpsbetalningar och royalties baserat på försäljning . I slutet av juli tecknade AbbVie ett exklusivt licensavtal med IGI Therapeutics värt 700 miljoner USD för läkemedelskandidaten ISB 2001, riktad mot cancer och autoimmuna sjukdomar. Avtalet ger AbbVie rättigheter att utveckla och kommersialisera ISB 2001 i Nordamerika, Europa, Japan och Kina. Det inkluderar även potentiella milstolpsbetalningar upp till 1,225 miljarder USD samt tvåsiffriga royalties. Detta kommer skapa stora nya intäkter för Abcellera🚀
- 8 aug.8 aug.Fin rapport! 🚀 Spännande framtid 🤩 ABCL635 och ABCL575 avancerar mot fas 1 kliniska prövningar i Q2 2026, med fokus på vasomotoriska symtom (menopaus) och atopisk dermatit. Stark likviditet med $810M tillgängligt, inklusive $633M i kontanter och $178M i icke-utspädande statlig finansiering. Framsteg med fyra molekyler för onkologi och autoimmuna sjukdomar, med lovande prekliniska data. 97 partnerinitierade programstart (upp 8% YoY) och 16 molekyler i klinik (upp 23% YoY).8 aug.8 aug.Clinical Program Updates AbCellera received Health Canada authorization to begin Phase I clinical trials for two internal antibody programs, ABCL635 (for vasomotor symptoms, VMS) and ABCL575 (for atopic dermatitis). Dosing has started for ABCL635, marking the company’s transition to a clinical-stage biotech. ABCL575’s trial was opened post-quarter, with dosing expected soon. A third program, ABCL688, targeting an undisclosed autoimmune indication, advanced into IND-enabling studies with an IND submission planned for mid-2026. ABCL635 Program for Vasomotor Symptoms ABCL635 is a potential first-in-class, nonhormonal NK3R antagonist designed to improve safety and dosing convenience. The Phase I trial is a randomized, placebo-controlled study assessing safety, pharmacokinetics, pharmacodynamics, and VMS frequency/severity with subcutaneous dosing. Primary endpoint is safety; key secondary endpoint is pharmacokinetics. Target engagement remains the main scientific risk, to be addressed via biomarkers and proof-of-concept studies. Initial safety and efficacy data are expected by mid-2026. Estimated enrollment around 56-60 participants across single and multiple ascending dose portions, with up to 80 postmenopausal women expected in proof-of-concept phases. There is a large market opportunity given many menopausal women are either contraindicated for or hesitant about hormone therapy, and NK3R antagonists are seen as complementary alternatives. Preclinical data supports a high concentration subcutaneous formulation aiming for once-monthly dosing. ABCL575 Program for Atopic Dermatitis ABCL575 targets the OX40 ligand, under development for moderate to severe atopic dermatitis and other immune/inflammatory conditions. The Phase I trial is double-blind, placebo-controlled, evaluating safety and tolerability in healthy participants. The antibody is engineered for half-life extension, with preclinical data indicating an approximate 67-day half-life to support twice-yearly subcutaneous dosing. Early focus is on bioavailability and pharmacokinetics; later stages likely to involve U.S. sites. Pipeline and Discovery Efforts The company continues internal discovery to build and expand the pipeline, adding new programs from discovery into IND-enabling studies in 2025. ABCL688 is the second program based on the GPCR and ion channel platform. Details are currently withheld for strategic reasons. Priorities for the year include advancing internal clinical programs, bringing clinical manufacturing capabilities online, and progressing discovery programs.8 aug.8 aug.Financial Performance and Position AbCellera ended Q2 2025 with approximately $580 million in cash and marketable securities plus $170 million in available government funding, totaling about $750 million in available liquidity. Revenue for the quarter was about $17 million, largely from research fees and a lump-sum licensing payment related to the Trianni acquisition. Research and development expenses were $39 million, down slightly from the prior year, reflecting ongoing investments in internal programs. Net loss was $35 million for the quarter, a slight improvement compared to $37 million in Q2 2024. Cash used in operating activities was approximately $44 million in the first half of 2025, with investment largely directed toward clinical manufacturing facilities. The new manufacturing facility is expected to be operational by year-end 2025. The company believes it has sufficient capital to fund pipeline investments for over three years. Regulatory and Development Considerations The recent PDUFA delay for Bayer's elinzanetant does not directly impact ABCL635’s regulatory path; the delay relates to Bayer needing to provide additional information. Regulatory focus for ABCL635 will center on demonstrating efficacy and safety, especially regarding liver toxicity signals seen with other NK3R antagonists and somnolence linked to NK1R activity, which AbCellera’s antibody avoids. Biomarkers such as LH, FSH, testosterone, and estradiol will be assessed early in trials as surrogate efficacy indicators before clinical proof-of-concept data. Clinical Trial Design and Strategy Initial Phase I studies include single ascending dose (SAD) cohorts with healthy men and postmenopausal women and multiple ascending dose (MAD) cohorts with only postmenopausal women. The company plans to engage with FDA for Phase II studies, likely including U.S. sites in later clinical phases for ABCL575. The clinical focus is to test dosing schedules, safety, bioavailability, and early efficacy signals supporting further development. Market and Competitive Landscape For ABCL635, the company projects a substantial market opportunity focused on patients unable or unwilling to use hormone therapy. The NK3R antagonist class has an established regulatory precedent, and AbCellera seeks to differentiate based on safety and dosing advantages. ABCL575 targets a growing class with broad potential beyond atopic dermatitis in immunology and inflammation. Intellectual Property and Legal General and administrative expenses include ongoing IP defense costs, reflecting ongoing protection of company innovations. Summary: AbCellera is advancing clinical programs ABCL635 and ABCL575 through early-stage human trials with data readouts expected in 2026, maintaining strong liquidity and investing in internal discovery and manufacturing capacity. The company is focused on demonstrating differentiated clinical profiles and progressing pipeline candidates efficiently.
- 24 juli24 juliNoen som vet om det var noen nyheter som kom, eller annet spesifikt, som kan ha påvirket det store hoppet på mandag? Jeg er opp 46% her etter å ha vært inne bare en snau måned, og har en lang tidshorisont, men lurer på om jeg skal ta ut litt gevinst i forkant av kvartalstallene, mon tro...25 juli25 juliSkulle säga att det är nu fram till helår 2026 som någonstans blir make or break året för Abcellera, så är det någonstans du ska ligga stilla, så är det här. Vi kan se en halvering av kursen, eller en dubblering inom bara månader. Och blir det en kraftig uppsving med så många miljoner aktier kortade så blir det gissningsvis en flerdubblering. Uppsida här är enorm men med rejäl risk. Som alltid.för 2 dagar sedanför 2 dagar sedanNo risk no reward right now I’m amazed by the advice I just got to buy some stock here
Kommentarerna ovan kommer från användare på Nordnets sociala nätverk Shareville och har varken redigerats eller på förhand granskats av Nordnet. Det innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna eller eventuella felaktigheter i automatiska översättningar.
Orderdjup
Antal
Köp
125
Sälj
Antal
100
Senaste avslut
| Tid | Pris | Antal | Köpare | Säljare |
|---|---|---|---|---|
| - | - | - | - |
Högst
-VWAP
Lägst
-Omsättning ()
VWAP
Högst
-Lägst
-Omsättning ()
Mäklarstatistik
Ingen data hittades
Kunder har även besökt
Företagshändelser
| Nästa händelse | |
|---|---|
Kalender är inte tillgänglig | |
| Tidigare händelser | ||
|---|---|---|
| 2025 Q2-rapport | 7 aug. | |
| 2025 Årsstämma | 12 juni | |
| 2025 Q1-rapport | 8 maj | |
| 2024 Q4-rapport | 27 feb. | |
| 2024 Årsrapport | 27 feb. |
Data hämtas från Morningstar, Quartr
Q2-rapport
14 dagar sedan‧27min
Nyheter & Analyser
Det finns för närvarande inga nyheter
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Företagshändelser
| Nästa händelse | |
|---|---|
Kalender är inte tillgänglig | |
| Tidigare händelser | ||
|---|---|---|
| 2025 Q2-rapport | 7 aug. | |
| 2025 Årsstämma | 12 juni | |
| 2025 Q1-rapport | 8 maj | |
| 2024 Q4-rapport | 27 feb. | |
| 2024 Årsrapport | 27 feb. |
Data hämtas från Morningstar, Quartr
Shareville
Delta i diskussionerna på SharevilleFå inspiration från tusentals portföljer och diskutera med andra duktiga investerare.
Logga in
- för 2 dagar sedanför 2 dagar sedanI januari 2025 meddelade AbCellera att de expanderar sitt samarbete med AbbVie för att utveckla nya T-cell-engagerande antikroppar (TCE) inom onkologi. Samarbetet innebär: • AbCellera leder forsknings- och upptäcktsarbetet med sin avancerade TCE-plattform. • AbbVie har rätt att vidareutveckla och kommersialisera de terapeutiska antikropparna som tas fram. • AbCellera får upfront-betalningar, forskningsersättningar, milstolpsbetalningar och royalties baserat på försäljning . I slutet av juli tecknade AbbVie ett exklusivt licensavtal med IGI Therapeutics värt 700 miljoner USD för läkemedelskandidaten ISB 2001, riktad mot cancer och autoimmuna sjukdomar. Avtalet ger AbbVie rättigheter att utveckla och kommersialisera ISB 2001 i Nordamerika, Europa, Japan och Kina. Det inkluderar även potentiella milstolpsbetalningar upp till 1,225 miljarder USD samt tvåsiffriga royalties. Detta kommer skapa stora nya intäkter för Abcellera🚀
- 8 aug.8 aug.Fin rapport! 🚀 Spännande framtid 🤩 ABCL635 och ABCL575 avancerar mot fas 1 kliniska prövningar i Q2 2026, med fokus på vasomotoriska symtom (menopaus) och atopisk dermatit. Stark likviditet med $810M tillgängligt, inklusive $633M i kontanter och $178M i icke-utspädande statlig finansiering. Framsteg med fyra molekyler för onkologi och autoimmuna sjukdomar, med lovande prekliniska data. 97 partnerinitierade programstart (upp 8% YoY) och 16 molekyler i klinik (upp 23% YoY).8 aug.8 aug.Clinical Program Updates AbCellera received Health Canada authorization to begin Phase I clinical trials for two internal antibody programs, ABCL635 (for vasomotor symptoms, VMS) and ABCL575 (for atopic dermatitis). Dosing has started for ABCL635, marking the company’s transition to a clinical-stage biotech. ABCL575’s trial was opened post-quarter, with dosing expected soon. A third program, ABCL688, targeting an undisclosed autoimmune indication, advanced into IND-enabling studies with an IND submission planned for mid-2026. ABCL635 Program for Vasomotor Symptoms ABCL635 is a potential first-in-class, nonhormonal NK3R antagonist designed to improve safety and dosing convenience. The Phase I trial is a randomized, placebo-controlled study assessing safety, pharmacokinetics, pharmacodynamics, and VMS frequency/severity with subcutaneous dosing. Primary endpoint is safety; key secondary endpoint is pharmacokinetics. Target engagement remains the main scientific risk, to be addressed via biomarkers and proof-of-concept studies. Initial safety and efficacy data are expected by mid-2026. Estimated enrollment around 56-60 participants across single and multiple ascending dose portions, with up to 80 postmenopausal women expected in proof-of-concept phases. There is a large market opportunity given many menopausal women are either contraindicated for or hesitant about hormone therapy, and NK3R antagonists are seen as complementary alternatives. Preclinical data supports a high concentration subcutaneous formulation aiming for once-monthly dosing. ABCL575 Program for Atopic Dermatitis ABCL575 targets the OX40 ligand, under development for moderate to severe atopic dermatitis and other immune/inflammatory conditions. The Phase I trial is double-blind, placebo-controlled, evaluating safety and tolerability in healthy participants. The antibody is engineered for half-life extension, with preclinical data indicating an approximate 67-day half-life to support twice-yearly subcutaneous dosing. Early focus is on bioavailability and pharmacokinetics; later stages likely to involve U.S. sites. Pipeline and Discovery Efforts The company continues internal discovery to build and expand the pipeline, adding new programs from discovery into IND-enabling studies in 2025. ABCL688 is the second program based on the GPCR and ion channel platform. Details are currently withheld for strategic reasons. Priorities for the year include advancing internal clinical programs, bringing clinical manufacturing capabilities online, and progressing discovery programs.8 aug.8 aug.Financial Performance and Position AbCellera ended Q2 2025 with approximately $580 million in cash and marketable securities plus $170 million in available government funding, totaling about $750 million in available liquidity. Revenue for the quarter was about $17 million, largely from research fees and a lump-sum licensing payment related to the Trianni acquisition. Research and development expenses were $39 million, down slightly from the prior year, reflecting ongoing investments in internal programs. Net loss was $35 million for the quarter, a slight improvement compared to $37 million in Q2 2024. Cash used in operating activities was approximately $44 million in the first half of 2025, with investment largely directed toward clinical manufacturing facilities. The new manufacturing facility is expected to be operational by year-end 2025. The company believes it has sufficient capital to fund pipeline investments for over three years. Regulatory and Development Considerations The recent PDUFA delay for Bayer's elinzanetant does not directly impact ABCL635’s regulatory path; the delay relates to Bayer needing to provide additional information. Regulatory focus for ABCL635 will center on demonstrating efficacy and safety, especially regarding liver toxicity signals seen with other NK3R antagonists and somnolence linked to NK1R activity, which AbCellera’s antibody avoids. Biomarkers such as LH, FSH, testosterone, and estradiol will be assessed early in trials as surrogate efficacy indicators before clinical proof-of-concept data. Clinical Trial Design and Strategy Initial Phase I studies include single ascending dose (SAD) cohorts with healthy men and postmenopausal women and multiple ascending dose (MAD) cohorts with only postmenopausal women. The company plans to engage with FDA for Phase II studies, likely including U.S. sites in later clinical phases for ABCL575. The clinical focus is to test dosing schedules, safety, bioavailability, and early efficacy signals supporting further development. Market and Competitive Landscape For ABCL635, the company projects a substantial market opportunity focused on patients unable or unwilling to use hormone therapy. The NK3R antagonist class has an established regulatory precedent, and AbCellera seeks to differentiate based on safety and dosing advantages. ABCL575 targets a growing class with broad potential beyond atopic dermatitis in immunology and inflammation. Intellectual Property and Legal General and administrative expenses include ongoing IP defense costs, reflecting ongoing protection of company innovations. Summary: AbCellera is advancing clinical programs ABCL635 and ABCL575 through early-stage human trials with data readouts expected in 2026, maintaining strong liquidity and investing in internal discovery and manufacturing capacity. The company is focused on demonstrating differentiated clinical profiles and progressing pipeline candidates efficiently.
- 24 juli24 juliNoen som vet om det var noen nyheter som kom, eller annet spesifikt, som kan ha påvirket det store hoppet på mandag? Jeg er opp 46% her etter å ha vært inne bare en snau måned, og har en lang tidshorisont, men lurer på om jeg skal ta ut litt gevinst i forkant av kvartalstallene, mon tro...25 juli25 juliSkulle säga att det är nu fram till helår 2026 som någonstans blir make or break året för Abcellera, så är det någonstans du ska ligga stilla, så är det här. Vi kan se en halvering av kursen, eller en dubblering inom bara månader. Och blir det en kraftig uppsving med så många miljoner aktier kortade så blir det gissningsvis en flerdubblering. Uppsida här är enorm men med rejäl risk. Som alltid.för 2 dagar sedanför 2 dagar sedanNo risk no reward right now I’m amazed by the advice I just got to buy some stock here
Kommentarerna ovan kommer från användare på Nordnets sociala nätverk Shareville och har varken redigerats eller på förhand granskats av Nordnet. Det innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna eller eventuella felaktigheter i automatiska översättningar.
Orderdjup
Antal
Köp
125
Sälj
Antal
100
Senaste avslut
| Tid | Pris | Antal | Köpare | Säljare |
|---|---|---|---|---|
| - | - | - | - |
Högst
-VWAP
Lägst
-Omsättning ()
VWAP
Högst
-Lägst
-Omsättning ()
Mäklarstatistik
Ingen data hittades